Identity
- Security key
- 21060
- Ticker
- RNAZ
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-07-09
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- RNAZ
Detail
Enriched 2026-08-14 20:47
- Market cap
- $3,567,080.97
- Shares outstanding (class)
- 1,058,481
- Shares outstanding (weighted)
- 1,058,481
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 12
- Location
- BOSTON, MA
- Description
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.